UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report

Bateman, R; Blennow, K; Doody, R; Hendrix, S; Lovestone, S; Salloway, S; Schindler, R; ... Zetterberg, H; + view all (2019) Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report. The Journal of Prevention of Alzheimer's Disease , 6 (3) pp. 169-173. 10.14283/jpad.2019.21. Green open access

[thumbnail of Zetterberg_Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development. An EU US CTAD Task Force Report_AAM.pdf]
Preview
Text
Zetterberg_Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development. An EU US CTAD Task Force Report_AAM.pdf - Accepted Version

Download (518kB) | Preview

Abstract

There is an urgent need to develop reliable and sensitive blood-based biomarkers of Alzheimer’s disease (AD) that can be used for screening and to increase the efficiency of clinical trials. The European Union-North American Clinical Trials in Alzheimer’s Disease Task Force (EU/US CTAD Task Force) discussed the current status of blood-based AD biomarker development at its 2018 annual meeting in Barcelona, Spain. Recent improvements in technologies to assess plasma levels of amyloid beta indicate that a single sample of blood could provide an accurate estimate of brain amyloid positivity. Plasma neurofilament light protein appears to provide a good marker of neurodegeneration, although not specific for AD. Plasma tau shows some promising results but weak or no correlation with CSF tau levels, which may reflect rapid clearance of tau in the bloodstream. Blood samples analyzed using -omics and other approaches are also in development and may provide important insight into disease mechanisms as well as biomarker profiles for disease prediction. To advance these technologies, international multidisciplinary, multi-stakeholder collaboration is essential.

Type: Article
Title: Plasma Biomarkers of AD Emerging as Essential Tools for Drug Development: An EU/US CTAD Task Force Report
Open access status: An open access version is available from UCL Discovery
DOI: 10.14283/jpad.2019.21
Publisher version: http://dx.doi.org/10.14283/jpad.2019.21
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
URI: https://discovery.ucl.ac.uk/id/eprint/10075238
Downloads since deposit
362Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item